MCL1 and myelodysplastic syndrome: Interestingly, specific inhibitors of SF3B1, such as Spliceostain A and Pladienolide B, can change the splicing of MCL‐1, CDK, and VEGF, and inhibit the proliferation of many tumors including MDS and small‐cell lung cancer [50, 51].